Use of a tetanus toxoid marker to allow differentiation of infected from vaccinated poultry without affecting the efficacy of a H5N1 avian influenza virus vaccine by James-Berry, C.M. et al.
Papers
October 30, 2010 | Veterinary Record
Papers
Use of a tetanus toxoid marker to allow 
differentiation of infected from vaccinated 
poultry without affecting the efficacy of  
a H5N1 avian influenza virus vaccine
C. M. James-Berry, D. Middleton, J. P. Mansfield, S. G. Fenwick, T. M. Ellis
Tetanus toxoid (TT) was assessed as a positive marker for avian influenza (AI) virus 
vaccination in chickens, in a vaccination and challenge study. Chickens were vaccinated twice 
with inactivated AI H5N2 virus vaccine, and then challenged three weeks later with highly 
pathogenic AI H5N1 virus. Vaccinated chickens were compared with other groups that were 
either sham-vaccinated or vaccinated with virus with the TT marker. All sham-vaccinated 
chickens died by 36 hours postinfection, whereas all vaccinated chickens, with or without the 
TT marker, were protected from morbidity and mortality following exposure to the challenge 
virus. Serological testing for H5-specific antibodies identified anamnestic responses to H5 in 
some of the vaccinated birds, indicating active virus infection. 
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RECENT epizootics of highly pathogenic avian influenza (HPAI) 
H5N1 virus in many countries in Asia, Europe, the Middle East and 
Africa have led to HPAI becoming endemic in some poultry popula-
tions. Subclinically infected wild birds shed virus into watery envi-
ronments and contaminate other terrestrial birds and domestic flocks, 
leading to potential transmission to human beings (Sturm-Ramirez 
and others 2004). Effective control of AI is hampered by many social 
and economic issues at local, regional and national levels (Macan-
Marker 2007). Most Asian countries with poultry industries con-
sisting of household, small farm and village flocks cannot choose to 
control AI using stamping-out as the principal means. The closure 
of live animal markets reduces income and animal protein supplies 
for families in rural communities. Inadequate or no compensation to 
farmers with infected flocks results in unwillingness to report out-
breaks to government authorities. Furthermore, trade sanctions related 
to countries with AI virus (AIV) infection place increased pressure on 
the national economies of exporting countries.
Vaccination, in combination with vigilant monitoring and bio-
security measures, has been recommended for effective HPAI con-
trol programmes (Swayne 2003, Lee and Suarez 2005). However, 
AI disease outbreaks still occur, probably due in part to incomplete 
vaccination of entire flocks and poor monitoring for AIV infection. 
Vaccination complicates serosurveillance for AIV based on haemag-
glutinin (H)-specific antibody testing, as both vaccinated and natu-
rally infected birds produce similar antibodies. It would be valuable 
to be able to distinguish vaccinated birds that are protected due to the 
presence of antibodies resulting from previous H5 vaccination from 
vaccinated birds that are silently infected by wild H5 AIV (Halvorsen 
2002). Furthermore, monitoring flocks would also check that vacci-
nation has been carried out with an approved/effective vaccine and 
delivered appropriately to the birds. Various strategies have been devel-
oped but have limitations for differentiating infected from vaccinated 
animals (DIVA), including testing for antibodies to heterologous neu-
raminidase (N), and internal viral antigens as negative endogenous 
markers. These strategies have been conceived to enhance virus sur-
veillance, prevent unnecessary culling and regulate poultry vaccina-
tion, movement and trade (Grogan and others 2007). At present, the 
heterologous N DIVA approach has been validated for use only with 
low pathogenicity AI (LPAI) virus surveillance in chickens and tur-
keys (Suarez 2005, Capua and Alexander 2006), and this strategy is 
affected by concurrent circulation of AIVs with the same N subtype 
in the poultry population. Many recent HPAI disease outbreaks have 
occurred in China, Vietnam and Indonesia, which have concurrent 
circulation of different AIV strains, making heterologous N DIVA 
approaches impractical. Also, the varying extent to which poultry vac-
cination is practised in these regions, coupled with poor biosecurity, 
currently sustains susceptible populations as reservoirs for the virus.
This paper describes a practical approach to virus surveillance 
based on the observation that avian species are naturally resistant to 
tetanus and are not seropositive for antibodies to tetanus toxoid (TT) 
(Hagan and Bruner 1961).
A positive exogenous marker for vaccination of birds, which allows 
testing by a cost-effective ELISA independent of circulating AIV strains, 
was developed by the authors. Recently, the authors reported 100 per 
cent seronegativity for naturally acquired antibodies to TT in over 
2250 chickens and ducks, but upon TT vaccination both species pro-
duced strong antibody responses to TT antigen (James and others 2007, 
2008). In ducks, the authors have recently found that the efficacy of vac-
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cination upon challenge with H5N1 AIV is unaffected by the inclusion 
of the TT marker in the vaccine (Chua and others 2010). However, the 
effect of the TT marker on vaccine efficacy in chickens remains to be 
elucidated. In this study, the authors evaluate possible interference of the 
TT marker on the efficacy of vaccination for the protection of chickens 
against HPAI H5N1 virus. Specific pathogen-free (SPF) chickens were 
vaccinated with a commercial inactivated H5N2 AIV isolate with and 
without covaccination with TT antigen. A challenge HPAI H5N1 virus 
isolate was administered to vaccinated and naive birds to compare mor-
bidity, mortality, antibody responses and viral shedding.
Materials and methods
Animals
Thirty 10-day-old SPF chickens (both males and females) were obtained 
from SPAFAS Australia and housed in the Biosafety Level 3 contain-
ment animal facility of the Commonwealth Scientific and Industrial 
Research Organisation (CSIRO), Australian Animal Health Laboratories 
(AAHL), Geelong, Australia. The chickens were supplied with commer-
cial compound feed and tap water ad libitum. TT-unvaccinated female 
Hy-Line Brown layer pullets (six to seven weeks old) were sourced from 
Altona Hatchery to provide sera used in the ELISA. Animal experimen-
tation was given prior approval by the CSIRO/AAHL and Murdoch 
University Animal Experimentation Ethics Committees.
Vaccine efficacy
All chickens received a priming vaccination at 19 days of age and 
a booster four weeks later, at 47 days of age. The AIV vaccine was a 
commercial inactivated AIV A/chicken/Mexico/232-CPA/94 H5N2 
(A/ch/Mex/94) water-in-emulsion preparation (Nobilis Influenza H5; 
Intervet). The TT vaccine was a water-in-oil emulsion consisting of 
a commercial prevaccine formulation of TT (estimated total protein 
30 mg/dose; Pfizer) mixed 1:1 (v/v) with Montanide ISA-70 VG (Seppic) 
as previously described by James and others (2007). One group of 10 
chickens was given inactivated AIV H5N2 vaccine (H5N2) alone and 
another group of 10 birds was covaccinated with TT and inactivated 
AIV H5N2 vaccine (TT/H5N2), given as two separate injections deliv-
ered at the same site. A control group of 10 chickens was sham-vacci-
nated with PBS at 19 and 47 days of age. The vaccines and PBS were 
administered as water-in-oil emulsions given subcutaneously in the 
dorsal midline at the lower end of the nape of the neck near the anterior 
dorsal thorax, in a volume of 0.5 ml for the priming dose and 1 ml for 
the booster dose. Three weeks after the second vaccination or sham 
vaccination, the chickens in all groups were challenged via the intrana-
sal, intraocular (eye drop) and intraoral routes with 0.5 ml of an AIV 
suspension containing 105.7 EID50 of HPAI A/chicken/Vietnam/08/2004 
H5N1 (A/ch/VN/04). A 1 ml syringe was used to administer the virus 
into the nares, the mouth and on to the conjunctiva. The challenge iso-
late was prepared from infected allantoic fluid (passed three times in SPF 
chicken eggs). Back-titration of the inoculum confirmed that the dose 
administered to each chicken was 105.7 EID50 H5N1 virus. Fourteen days 
after the challenge, all the surviving chickens were euthanased.
Morbidity and mortality
After challenge, the chickens were observed twice daily throughout 
the study for clinical signs of HPAI.
Antibody responses
Blood samples were obtained from each chicken before the first and 
second vaccinations, immediately before the challenge, and from each 
chicken that was still alive 14 days after the challenge. Blood samples 
were collected by venepuncture from the wing veins. Oropharyngeal 
and cloacal swabs from each challenged bird were taken on days 2, 3, 
4 and 7 after challenge. The swabs were placed in isotonic PBS (pH 
7.0 to 7.4) containing the antibiotics penicillin and streptomycin. The 
samples were frozen at −80°C before processing for AIV isolation.
H5-specific antibody titres were determined by haemagglutination 
inhibition (HI) assay using procedures previously described (WHO 
2002) and homologous AI challenge virus. The HI titre was deter-
mined as the highest dilution of serum giving complete  inhibition 
of haemagglutination, and data were expressed as the reciprocal end-
point dilution of sera from individual chickens and mean reciprocal 
titre log2
 + standard error of the mean (se) for each group.
Serum antibody levels to TT were determined by ELISA (James 
and others 2007). Briefly, 0.012 µg purified TT antigen (List Biological 
Laboratories) was used as the coating antigen. Primary antibody was 
assayed in duplicate (diluted 1:200) from individual chickens at each 
time point, and rabbit anti-chicken F(ab´)2 antibody conjugated to horse-
radish peroxidase (diluted 1:40,000; Chemicon International) was used 
to label the primary antibody. The optical density (OD) of the plates 
was read at 450 nm with 630 nm reference wavelengths using a spec-
trophotometer (Bio-Rad Model 680). Controls included in each plate 
were six replicates of the negative control (pooled pre-bleeds [control 
sera taken before vaccination] from six naive Hy-Line Brown chickens, 
diluted 1:200) and six replicates of the positive control (pooled sera, 
diluted 1:200, collected at week 6 from the same six chickens, which 
had been vaccinated twice with 1 ml of the commercial tetanus vaccine 
for horses, Equivac T (CSL) at weeks 0 and 4. The level of TT antibody 
present in each serum sample was calculated using the formula:
Mean OD test –  
Mean OD negative control%TT antibody positive = x 100
Mean OD positive control –  
Mean OD negative control
Virus shedding
Supernatant fluids of oropharyngeal and cloacal swab samples from 
the chickens after challenge were inoculated into the allantoic cavity 
FIG 1: Antibody responses to tetanus toxoid (TT) and avian 
influenza virus (AIV) H5 in chickens vaccinated twice at weeks 0 
and 4. Groups of 10 chickens were vaccinated with the TT/H5N2 
vaccine, inactivated H5N2 AIV vaccine alone or sham-vaccinated 
with saline and challenged at week 7 with 105.7 EID50 highly 
pathogenic H5N1 virus. Antibody levels in sera were monitored 
from week 0 to 9 after vaccination. (a) Mean (se) percentage 
positive levels of TT-specific antibodies determined by ELISA 
using TT antigen. The value for positive control sera was obtained 
from replicates of TT-vaccinated chickens (mean OD450nm 1.16) and 
the value for negative control sera was derived from replicates 
of naive chickens (mean OD450nm 0.04). (b) Mean log2 (se) H5 
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of three embryonated chicken eggs at nine to 11 days’ incubation. The 
eggs were incubated at 35 to 37°C for four to seven days. Allantoic flu-
ids from the eggs were tested for haemagglutinating activity. Samples 
positive by isolation were further titrated in embryonated chicken 
eggs by serial 10-fold dilution of residual supernatant. Endpoint titres 
expressed as EID50/0.1 ml represented the last reciprocal dilution of 
allantoic fluid causing infection of 50 per cent of the eggs, demon-
strated by dying or dead embryos.
Haemagglutination titres from allantoic fluids were determined as 
described previously (OIE 2009). Briefly, chicken red blood cells were 
mixed with serial dilutions of allantoic fluid and incubated at 4°C for 
60 minutes. The highest dilution giving complete haemagglutination 
was calculated as the endpoint titre.
Statistical analysis
The two-tailed unpaired Student’s t test assuming unequal variance 
between means was used to determine statistical significance (set at 
P<0.05).
Results
Efficacy of TT and inactivated AIV (H5N2) covaccination 
in chickens challenged with HPAI virus (H5N1)
Following challenge with a 105.7 EID50 dose of HPAI virus isolate A/ch/
VN/04 (H5N1), several chickens in the control group showed slight 
depression 24 hours after exposure to infectious virus. By 36 hours 
after challenge, all the controls had died, and their deaths were attrib-
uted to peracute infection with AIV. In contrast, all the vaccinated 
chickens survived and remained clinically healthy following the viral 
challenge. Specifically, depression, respiratory signs, head oedema, 
cyanosis, subcutaneous haemorrhages, inappetence and diarrhoea 
were not observed during the two-week observation period following 
virus challenge in chickens vaccinated with inactivated AIV (H5N2) 
or the TT/H5N2 vaccine.
Antibody responses to TT and H5 in chickens 
covaccinated with TT and inactivated AIV (H5N2)  
vaccine and challenged with HPAI virus (H5N1)w
Before vaccination, all 30 chickens were negative for antibodies to 
TT. Strong antibody responses to TT were elicited in TT/H5N2-
vaccinated chickens (Fig 1a). Four weeks after vaccination, a strong 
antibody response specific for TT was observed, which peaked at 
weeks 7 to 9. At two weeks after the AIV H5N1 challenge (week 
9), there was no significant increase in antibody levels to TT. As 
 expected, no TT-specific antibody responses were found in the control 
group or the group vaccinated only with inactivated AIV H5N2 at 
any time point.
The H5 HI antibody titres were determined for individual chickens 
(Table 1) and H5 HI titres for the vaccinated groups were also expressed 
as mean log2 + se (Fig 1b). All chickens were negative for antibody to 
H5 before virus vaccination or sham-vaccination. The control birds 
remained negative for HI antibody before challenge. All the birds in the 
AIV H5N2-vaccinated and TT/H5N2-vaccinated groups seroconvert-
ed to H5 following priming, with no significant difference in H5 HI 
titres found between the groups at each time point.
Following the AIV challenge, five chickens in the H5N2-
vaccinated group and two in the TT/H5N2-vaccinated group showed 
a fourfold rise in H5 HI antibody titre at day 14 after challenge, sug-
gesting an anamnestic response to the H5 of the challenge virus (Table 
1). This anamnestic antibody response to H5 may imply that viral rep-
lication had occurred in these individual birds, which was also evident 
at the group level (Fig 1b, week 9). A significant increase in the mean 
H5 HI antibody titres was observed over the two weeks following 
challenge with the live AIV H5N1 isolate for the H5N2-vaccinated 
group (P<0.005) and the TT/H5N2-vaccinated group (P<0.01).
Virus shedding in chickens covaccinated with TT  
and inactivated AIV H5N2 and challenged with  
HPAI virus (H5N1)
Virus was not reisolated from the cloacal swabs from any vaccinated 
chicken on days 2, 3, 4 or 7 after challenge (data not shown). However, 
in the group vaccinated with inactivated AIV (H5N2), HPAI virus was 
reisolated from five of 10 oropharyngeal swabs on day 2 postchallenge 
(Table 2). Interestingly, these positive samples were from four of the 
five chickens in this group that displayed an anamnestic response to 
H5. Further virus isolations were obtained from three of these chick-
ens on either day 3 or day 4 after challenge.
In the TT/H5N2-vaccinated group, HPAI virus was reisolat-
ed from eight of 10 oropharyngeal swabs on day 2 after challenge 
(Table 2). The two birds that showed an anamnestic response to H5 
were among the birds that were positive for virus isolation. Further 
virus isolations were made from three of these chickens on either day 
3 or day 7 postchallenge.
Challenge virus was detected intermittently in 10 of 40 oropha-
ryngeal swabs from the inactivated AIV H5N2-vaccinated group 
and in 11 of 40 oropharyngeal swabs from the TT/H5N2-vaccinated 
group throughout the seven-day sampling period after challenge. In 
both groups of vaccinated chickens, the titre of virus isolated from 
the oropharyngeal swabs from virus-positive chickens after challenge 
was very low, 101 EID50/0.1 ml for 12 chickens and 10
1.5 EID50/0.1 ml 
for one TT/H5N2-vaccinated bird (Table 2). There was no significant 
difference in the geometric mean titres of virus shed intermittently in 
the oropharynx between the inactivated AIV H5N2-vaccinated and 
the H5N2/TT-vaccinated groups after challenge.
Discussion
This study demonstrated that vaccination of chickens with inacti-
vated AIV H5N2 or covaccination with TT/H5N2 resulted in all 
vaccinated chickens being protected from morbidity and mortality 
following challenge with a HPAI H5N1 virus that was rapidly and 
uniformly lethal in unvaccinated chickens. Although all the vacci-
nated chickens survived challenge with the HPAI H5N1 virus isolate, 
several chickens vaccinated with either the inactivated AIV H5N2 
TABLE 1: Haemagglutination inhibition (HI) antibody titres to H5 
in groups of 10 chickens vaccinated twice at weeks 0 and 4 with 
inactivated H5N2 avian influenza virus (AIV) or tetanus toxoid 
(TT)/H5N2 marker vaccine, or left unvaccinated, and challenged 
with live HPAI H5N1 virus at week 7
H5 HI antibody titre†
Week Control H5N2 vaccinated TT/H5N2 vaccinated
0 <4, <4, <4, <4, <4, <4, <4, <4, <4, <4, <4, <4, <4, <4, <4,
<4, <4, <4, <4, <4 <4, <4, <4, <4, <4 <4, <4, <4, <4, <4
4 <4, <4, <4, <4, <4, 256, 128, 128, 32, 128, 128, 64, 128, 128, 512,
<4, <4, <4,<4, <4 512, 1024, 512, 256, 128 128, 16, 128, 128, 128
7 <4, <4, <4, <4, <4, 128, 64, 256, 32, 128, 64, 64, 128, 128, 512,
<4, <4, <4, <4, <4 256, 2048, 256, 512, 128 64, 32, 128, 256, 128
 9 NA* 128, 2048, 2048, 512, 256 128, 512, 512, 2048, 2048,
512, >4096, 2048, 2048, 1024 128, 128, 512, 512, 128
* Not available for testing as all chickens had died
† HI titres shown in bold indicate a fourfold rise in antibody titre from previous sampling 
of individual chickens
TABLE 2: Virus isolation from oropharyngeal swabs from groups 
of 10 chickens vaccinated twice with inactivated H5N2 avian 
influenza virus (AIV) or tetanus toxoid (TT)/H5N2 marker vaccine 
after challenge with live HPAI H5N1 virus
Virus isolation and titre (EID
50
/0.1 ml)*
Day H5N2 vaccine TT/H5N2 vaccine
2 – + + + – 5/10 + + + (101.5) + – 8/10
+ – – – + – + + + +
3 – – – + – 2/10 – – – – – 1/10
– – – – + – – + – –
4 – – + + – 3/10 – – – – – 0/10
– – – – + – – – – –
7 – – – – – 0/10 – + – – – 2/10
– – – – – – + – – –
* Virus isolation was performed using embryonated chicken eggs and expressed 
as positive (+) or negative (–) for individual chickens 1 to 10 (left to right in rows), 
corresponding to Table 1. The EID
50
 titres for positive virus isolations were 101 
EID
50
/0.1 ml except for the positive sample shown in parentheses for day 2 after 
challenge in the TT/H5N2 group
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vaccine or the TT/H5N2 vaccine did become infected after the chal-
lenge. This was evident as a very low level of intermittent viral shed-
ding from the oropharynx (101-1.5 EID50/0.1 ml) and boosting of H5 
antibody titres, suggesting an anamnestic response in some chick-
ens after challenge with heterologous AIV H5N1. However, there 
was no significant difference in the frequency of shedding or the 
titres of virus shed intermittently from the oropharynx between 
the groups of birds vaccinated with the AIV H5N2 and TT/H5N2 
vaccines. Virus was not reisolated from the cloacal swabs from any 
vaccinated chicken, suggesting that faecal shedding was negligible 
and that environmental contamination from infected faeces would 
have been substantially reduced. Although the level of virus shed-
ding in unvaccinated chickens two days after challenge could not 
be determined because all of these chickens had died by 36 hours 
after the challenge, the level of virus shedding from the oropharynx 
of vaccinated chickens was approximately 100-fold lower than the 
infectious dose required to infect chickens (103.2 EID50/0.1 ml) under 
standard laboratory conditions with this virus (D. Middleton, per-
sonal communication). In other studies of inactivated AIV H5N2 
vaccines in chickens that were challenged with the same lineage of 
H5N1 AIV, the level of virus shedding detected by cloacal swabs 
(mean titre of 105.8 EID50/ml) and oropharyngeal swabs (mean titre 
of 106.16 EID50/ml) in unvaccinated control chickens two days after 
challenge was substantially higher (104- to 10
5-fold) than the virus 
shedding found in the present study. Furthermore, a similar propor-
tion of vaccinated chickens shed virus from the oropharynx on day 
2 after challenge with titres of 101.23-1.78 EID50/ml in the oropharynx 
and 101.00-1.53 EID50/ml in the cloaca (Swayne and others 2006).
AI can be a serious threat to animal and public health, as shown 
by the current epizootic of HPAI H5N1 viruses (Capua and Alexander 
2007). It is of particular concern that all 16 H and nine N AIV sub-
types continue to circulate in wild Anseriformes and Charadriformes. 
To date, H5 and H7 subtypes have spread to domestic poultry, and 
with increased virulence and transmission some have developed into 
HPAI viruses. Vaccination of poultry can be used as a means of con-
trolling AI by protecting birds from disease and reducing virus shed-
ding in flocks (Ellis and others 2004). However, despite vaccination, 
some countries have continued to experience H5N1 AIV outbreaks, 
which highlights the importance of improved biosecurity, quarantine, 
elimination of actively infected birds and enhanced virus surveillance 
in conjunction with vaccination (Swayne 2006). Many recent HPAI 
H5N1 disease outbreaks have occurred in Asia, particularly Indonesia, 
Vietnam and China, where vaccination of poultry is practised to vary-
ing extents, improvement of biosecurity practices is difficult and sero-
logical surveillance is complicated by concurrent use of vaccination 
(Capua and Marangon 2006).
A range of DIVA strategies have been considered and developed for 
incorporation into surveillance programmes for AI in poultry (Grogan 
and others 2007). Subunit vaccines based on recombinant expressed 
H5 antigen provide serological differentiation of infected from vac-
cinated birds by testing for antibody to viral antigens such as N1, M, 
NP or NS1. Other DIVA strategies include the use of marker vaccines 
with deletion mutants of the virus. This approach was first described 
for vaccination of pigs with attenuating deletion mutant viruses lack-
ing viral proteins that are not essential for replication but providing 
protection from Aujeszky’s disease (van Oirschot and others 1990). 
Infected pigs could be detected by ELISA for antibody responses to 
the target viral protein (gI), whereas vaccinated pigs would appear 
sero negative, as the vaccine virus lacked gI. Culling of gI-positive pigs 
would aid in eradication of the disease in countries where vaccination 
was used. However, the construction of such deletion mutant vac-
cines for strains of AIV would not be easy or cost-effective for poultry. 
Another approach is to use sentinel birds; this method is used in Hong 
Kong and some regions of Indonesia, but is not practical for regular 
monitoring in other Asian countries where flocks are dispersed and 
are mainly backyard or village flocks.
Before vaccination, all 30 chickens in the present study were 
negative for antibodies to TT. This finding supports the authors’ 
earlier observations of 100 per cent seronegativity for antibodies 
to TT in chickens and ducks of various strains and at various geo-
graphical locations (James and others 2007, 2008, Chua and others 
2010). This brings the total number of poultry screened for antibod-
ies to TT to 2294, with all being seronegative. These results provide 
a significant basis for the use of TT as a marker of vaccination in 
poultry.
A marker vaccine containing TT for inactivated AIV vaccines in 
poultry has many advantages over current DIVA approaches and has 
attributes that would enhance AIV surveillance and control in small-
scale and village poultry systems. Although the inclusion of TT in 
vaccines adds incrementally to the cost, which is very low (approxi-
mately AU$0.20 per bird), the benefits are in the considerable cost 
savings for the serological tests, as the ELISA for antibodies to TT is 
substantially cheaper than the neuraminidase inhibition test. Thus, 
the use of the TT marker underwrites a more economical serological 
DIVA approach than current alternatives used in the field. Addition 
of the TT marker to approved H5 AIV vaccines for poultry would 
allow serological identification of vaccinated flocks in farming sys-
tems where record keeping is poor or non-existent. Moreover, the 
increased use of unapproved vaccines and uncontrolled vaccination 
with improper distribution and administration of vaccines poses a 
significant future threat for AI outbreaks in poultry (Peyre and others 
2009). This situation for vaccination programmes can be regulated 
with the TT marker approach, limiting the potential of the virus to 
mutate and become a pandemic pathogen. Concurrent H5 antibody 
testing (by HI) could establish that vaccinated flocks were achiev-
ing H5 antibody titres that could protect them from challenge and 
significantly reduce virus excretion. The TT marker strategy could 
be used as a tool to monitor compliance with H5 AIV vaccination 
programmes and to check on the vaccine quality and coverage for 
poultry entering live bird markets. Serological evidence of compliance 
with the use of approved/effective vaccines could be regulated, as birds 
would need to show positive antibody responses to TT with concur-
rent H5 antibody levels that could be expected to protect them from 
AIV challenge and significantly reduce virus excretion before they 
could be sold at market.
Investigation of deaths in AIV H5-vaccinated flocks could incorpo-
rate testing for antibodies to the TT marker. If dead birds in vaccinated 
flocks were confirmed to be infected with HPAI H5N1 virus, testing 
for TT antibody could establish whether they had been vaccinated in 
the past. Testing the dead birds’ cohort for TT- and H5-specific anti-
body responses could determine if the level of vaccination coverage in 
the flock was poor, and, depending on the H5-specific antibody titres 
present, whether vaccination was suboptimal or the vaccine did not 
elicit protection against the circulating field H5N1 AIV. The authors 
have observed that antibodies to TT can be detected in heart blood 
from dead vaccinated chickens kept at 4°C for 50 hours after death 
and in dead chickens kept at ambient temperature (24°C to 30°C) for 
at least 30 hours (data not shown).
Furthermore, field use of the TT marker with inactivated AIV 
H5 vaccines could establish normal response curves for TT- and 
H5-specific antibodies in vaccinated uninfected flocks. The authors 
have previously reported that the TT antibody response in chickens 
vaccinated twice with a combined inactivated LPAI virus H6N2 and 
TT vaccine is sustained to 53 weeks after vaccination (the duration 
of the study), and that the titre at week 53 was not significantly dif-
ferent from the titre obtained at week 6, but that the H6 HI antibody 
response peaked at week 6 (9 log2) and then declined (week 53, 5 log2) 
(James and others 2007). These antibody responses could establish a 
standard profile of the ratio of TT/H5 HI antibody titre at any given 
time after vaccination. If altered ratios of antibodies to TT/H5, with 
higher than expected H5 antibody titres, were found, then this could 
indicate an anamnestic response to recent AIV H5N1 infection, 
requiring further virological investigation of the flock.
The authors conclude that chickens vaccinated twice with either 
inactivated AIV H5N2 vaccine or H5N2/TT vaccine are fully pro-
tected from morbidity and mortality associated with challenge by a 
lethal dose of a heterologous HPAI H5N1 virus. Moreover, covacci-
nation with TT and H5N2 AIV antigens did not interfere with the 
antibody responses to each of the antigens individually. Although low 
levels of intermittent viral shedding occurred after the viral challenge, 
this was similar in terms of both the proportion of chickens shedding 
virus and the virus titres shed to the results of other studies with such 
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vaccines (Swayne, and others 2006), and the titres of virus shed were 
not significantly different between the H5N2-vaccinated and H5N2/
TT-vaccinated groups. The benefits of the TT marker approach for 
AIV vaccination in poultry include specific antibody response data 
allowing evaluation of both vaccine coverage and effectiveness at flock 
or village level after virus exposure. Furthermore, concurrent HI testing 
and TT serology will probably provide information on altered ratios 
of these antibodies and assist in identifying exposure to field strains 
of AIV in vaccinated poultry flocks. Thus, the TT marker may be 
used as a tool for the identification of AIV vaccination of poultry and 
assist veterinary authorities in serosurveillance of HPAI H5N1 virus 
in countries using vaccination for the control of recurrent H5N1 AIV 
outbreaks. An integrated effort from the veterinary and medical com-
munities in the control of zoonotic HPAI viruses is urgently required 
for improved global health (Capua and Cattoli 2010).
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